Mika has been selected a participant in the inaugural cohort of the US government’s CancerX Accelerator program, launched as part of the “Cancer Moonshot” initiative, aiming to reduce cancer-related mortality and improve patient quality of life. Mika will collaborate with leading companies and CancerX Champions to develop digital innovations in oncology, with a focus on improving patient outcomes. Selected through a rigorous evaluation process involving prominent industry leaders, Mika aims to leverage this opportunity to enhance its impact on cancer care and expand its market presence, including in the USA.
It is a great confirmation of our work to be among the first members of this groundbreaking funding program, and especially that we were able to convince four outstanding sponsors to work together. This will enable us to achieve our goal of improving the quality of life and survival rate of cancer patients even more effectively. This is also an important step for our upcoming market entry in the USA
says Dr. Gandolf Finke, founder and managing director of Mika.
Access to their full press release here